Related Experiment Video
Updated: Jul 8, 2025
Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
Published on: June 28, 2019
β-adrenergic receptor signaling mediated by β-arrestins and its potential role in heart failure
Preston C Nibley1,2, Sudha K Shenoy1,2
1Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Insights
Understanding beta-arrestin signaling in heart failure (HF) is crucial for treating cardiovascular disease (CVD). Beta-arrestins modulate beta-adrenergic receptor (β-AR) pathways, offering potential cardioprotective strategies.
Area of Science:
- Cardiovascular Biology
- Molecular Pharmacology
- Cellular Signaling
Background:
- Heart failure (HF) lethality, especially post-SARS-CoV-2 infection (PASC)-related myocarditis, highlights the need to understand cardiovascular disease (CVD) cellular pathways.
- Catecholamine-binding β-adrenergic receptors (β-ARs) are key G protein-coupled receptors (GPCRs) in cardiovascular regulation.
- β-arrestins play a dual role in β-AR signaling: quenching G protein pathways and initiating independent cascades.
Purpose of the Study:
- To elucidate the complex signaling mechanisms of β-ARs, focusing on the multifaceted role of β-arrestins in cardiovascular physiology and pathology.
- To explore how β-arrestin interactions and post-translational modifications influence β-AR signaling.
- To investigate the potential cardioprotective effects of β-arrestin-biased agonism and allosteric modulation.
Main Methods:
- Review and synthesis of existing literature on β-AR and β-arrestin signaling pathways.
- Analysis of GPCR signaling dynamics, including canonical G protein pathways and β-arrestin-mediated events.
- Examination of the impact of post-translational modifications and allosteric modulators on receptor activity.
Main Results:
- β-arrestins are critical regulators of β-AR signaling, capable of both inhibiting G protein cascades and initiating distinct signaling pathways.
- Post-translational modifications significantly influence β-arrestin function and downstream signaling outcomes.
- β-arrestin-biased ligands, such as carvedilol, and allosteric modulators demonstrate potential for cardioprotection by selectively targeting β-AR signaling.
Conclusions:
- The intricate nature of GPCR signaling necessitates a deeper understanding of β-arrestin's role in cardiovascular health and disease.
- Targeted modulation of β-AR signaling through β-arrestin bias and allosteric mechanisms offers promising therapeutic avenues for cardiovascular conditions.
- Further research into novel drugs and endogenous modifications is warranted to harness the full cardioprotective potential of these pathways.
Abstract:
The lethality of heart failure (HF), particularly in the context of post-acute sequelae SARS-CoV-2 infection (PASC)-related myocarditis, necessitates the discovery of the cellular pathways implicated in cardiovascular disease (CVD). We summarize the signaling mechanisms of the catecholamine-binding β-adrenergic receptors (β-ARs), with an emphasis on the role of β-arrestins. β-ARs, a subset of G protein-coupled receptors (GPCRs), canonically propagate signals through heterotrimeric G proteins. However, since their discovery in the late 1980s, β-arrestins have been shown to, both (i) quench G protein signaling and (ii) initiate their own independent signaling cascades, which is influenced by post-translational modifications. β-arrestin-biased agonism by the beta-blocker carvedilol and its allosteric modulation can serve a cardioprotective role. The increasingly labyrinthine nature of GPCR signaling suggests that ligand-dependent β-AR signaling, either stimulated by an agonist or blocked by an antagonist, is selectively enhanced or suppressed by allosteric modulations, which are orchestrated by novel drugs or endogenous post-translational modifications.
Related Concept Videos
01:26Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
01:22Heart Failure Drugs: β-Blockers
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:17Antihypertensive Drugs: Action of β1 Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:27Adrenergic Receptors (Adrenoceptors): Classification
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...